Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 57-64

  Kishiki, Tomokazu ^a   Ohnishi, Hiroaki ^a   Masaki, Tadahiko ^a   Ohtsuka, Kouki ^a   Ohkura, Yasuo ^a   Furuse, Jyunji ^a   Sugiyama, Masanori ^a   Watanabe, Takashi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti EGFR therapy; Colorectal cancer; KRAS mutation; MET; PTEN

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PTEN PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME; VERY ELDERLY; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84903150405     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3179     Document Type: Article

References (36)

1. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972, 2008.
2. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E and Ciardiello F: Implications for KRAS status and EGFRtargeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527, 2009.
3. Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE and Schaefer KL: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol 139: 201-209, 2013.
4. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
5. Saridaki Z, Tzardi M, Papadaki C, et al: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 6: e15980, 2011.
6. O'Neil BH: Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. Semin Radiat Oncol 13: 441-453, 2003.
7. Adlard JW, Richman SD, Seymour MT and Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3: 75-82, 2002. (Pubitemid 34162977)
8. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007. (Pubitemid 46548951)
9. Bando H, Yoshino T, Yuki S, et al: Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. Jpn J Clin Oncol 42: 1146-1151, 2012.
10. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C and Van Cutsem E: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30: 3570-3577, 2012.
11. Guerrero S, Casanova I, Farré L, Mazo A, Capellà G and Mangues R: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorageindependent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60: 6750-6756, 2000.
12. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820, 2010.
13. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R and Wiezorek J: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31: 759-765, 2013.
14. Gajate P, Sastre J, Bando I, et al: Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 11: 291-296, 2012.
15. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.
16. Ulivi P, Capelli L, Valgiusti M, et al: Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med 10: 87, 2012.
17. Kato S, Iida S, Higuchi T, et al: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121: 1771-1778, 2007. (Pubitemid 47417296)
18. Inno A, Di Salvatore M, Cenci T, et al: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 10: 325-332, 2011.
19. Guo A, Villén J, Kornhauser J, et al: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697, 2008. (Pubitemid 351171770)
20. Sattler M, Reddy MM, Hasina R, Gangadhar T and Salgia R: The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3: 171-184, 2011.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
22. Ohnishi H, Ohtsuka K, Ooide A, Matsushima S, Goya T and Watanabe T: A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. Diagn Mol Pathol 15: 101-108, 2006. (Pubitemid 44350487)
23. Torres J, Navarro S, Roglá I, et al: Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur J Cancer 37: 114-121, 2001. (Pubitemid 32119368)
24. Dua R, Zhang J, Parry G and Penuel E: Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay. PLoS One 6: e15932, 2011.
25. Murray S, Karavasilis V, Bobos M, et al: Molecular predictors of response to tyrosine kinase inhibitors in patients with non-smallcell lung cancer. J Exp Clin Cancer Res 31: 77, 2012.
26. Lin B, Utleg AG, Gravdal K, et al: WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res 14: 1397-1406, 2008. (Pubitemid 351413921)
27. Halvorsen OJ, Rostad K, Øyan AM, et al: Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res 13: 892-897, 2007. (Pubitemid 46340364)
28. Zeng ZL, Wu WJ, Yang J, et al: Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. J Transl Med 10: 181, 2012.
29. Pandolfi PP: Breast cancer - loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337-2338, 2004.
30. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK and Strom SC: Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811, 2000. (Pubitemid 30180235)
31. Takeuchi H, Bilchik A, Saha S, et al: c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9: 1480-1488, 2003. (Pubitemid 36418405)
32. Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289-300, 2002. (Pubitemid 37328782)
33. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
34. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ and Tang JL: KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: A systematic review and meta-analysis. Cancer 119: 714-721, 2013.
35. Strumberg D, Scheulen ME, Schultheis B, et al: Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 106: 1722-1727, 2012.
36. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506, 2012.